Opthea Limited (NASDAQ:OPT – Free Report) – Research analysts at HC Wainwright boosted their FY2025 earnings estimates for Opthea in a note issued to investors on Tuesday, September 3rd. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.25) per share for the year, up from their prior estimate of ($2.08). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Opthea’s current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Opthea’s FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.03) EPS and FY2028 earnings at $0.19 EPS.
Opthea Stock Up 3.1 %
Shares of Opthea stock opened at $2.98 on Friday. The firm’s 50 day moving average price is $2.35 and its 200-day moving average price is $2.93. Opthea has a 52-week low of $1.60 and a 52-week high of $4.40.
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Stories
- Five stocks we like better than Opthea
- How to Use Stock Screeners to Find Stocks
- Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
- Overbought Stocks Explained: Should You Trade Them?
- Is There an AI Bubble: Yes? No? Maybe
- ESG Stocks, What Investors Should Know
- GameStop in Rebound Mode: Is Now the Time to Buy?
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
